COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR PATIENTS WITH CHRONIC HCV IN THE NETHERLANDS

被引：1
|
作者：
Gaultney, J. [1 ]
de Knegt, R. J. [2 ]
Fassler, P. [3 ]
Visser, S. [3 ]
Johnson, S. [4 ]
机构：
[1] Mapi Grp, Houten, Netherlands
[2] Erasmus MC, Rotterdam, Netherlands
[3] AbbVie BV, Hoofddorp, Netherlands
[4] Medicus Econ LLC, Milton, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1504
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN71
引用
收藏
页码：A588 / A588
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease
    Aljarallah, Badr M.
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2024, 16 : S2224 - S2227
  • [32] REAL LIFE EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR AND RIBAVIRIN REGIMEN IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS
    Jinga, Mariana
    Balaban, Vasile Daniel
    Ionita-Radu, Florentina
    Costache, Raluca
    Nuta, Petrut
    Bucurica, Sandica
    Popescu, Andrada
    Stoica, Victor
    Vutcanu, Oana
    Milicescu, Mihaela
    Stefan, Ion
    Macadon, Bogdan
    Farcas, Alice
    Naftanaila, Florica
    Alexandru, Aurelia
    Robu, Georgiana C.
    GASTROENTEROLOGY, 2017, 152 (05) : S1148 - S1148
  • [33] Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin
    Fabrizio, Claudia
    Saracino, Annalisa
    Milella, Michele
    Resta, Francesco
    Angarano, Gioacchino
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (01) : 115 - 116
  • [34] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients
    Nicole Loo
    Eric Lawitz
    Naim Alkhouri
    Jennifer Wells
    Carmen Landaverde
    Angie Coste
    Rossalynn Salcido
    Michael Scott
    Fred Poordad
    World Journal of Gastroenterology, 2019, (18) : 2229 - 2239
  • [35] Glycemic Control in Patients Undergoing Treatment With Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection
    Bacinschi, Xenia
    Mercan-Stanciu, Adriana
    Toma, Letitia
    Zgura, Anca
    Bacalbasa, Nicolae
    Ifrim, Chen-Peng
    Diaconu, Camelia
    Iliescu, Laura
    Toma, Radu Valeriu
    IN VIVO, 2022, 36 (03): : 1438 - 1443
  • [36] HEALTH-ECONOMIC EVALUATION OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR TREATMENT OF CHRONIC GENOTYPE 1 HCV INFECTION IN GERMANY
    Sroczynski, G.
    Conrads-Frank, A.
    Kuehne, F.
    Muehlberger, N.
    Froehlich, H.
    Dietz, B.
    Samp, J. C.
    Zeuzem, S.
    Siebert, U.
    VALUE IN HEALTH, 2016, 19 (07) : A512 - A512
  • [37] HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
    Asselah, Tarik
    Bruno, Savino
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1430 - 1433
  • [38] Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
    Yaras, Serkan
    Ucbilek, Enver
    Ozdogan, Osman
    Ates, Fehmi
    Altintas, Engin
    Sezgin, Orhan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (04): : 331 - 335
  • [39] Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection
    Gillian M. Keating
    Drugs, 2016, 76 : 1203 - 1211
  • [40] Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection
    Keating, Gillian M.
    DRUGS, 2016, 76 (12) : 1203 - 1211
12345